Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C.

Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

2.

Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.

Zaccaria GM, Ferrero S, Rosati S, Ghislieri M, Genuardi E, Evangelista A, Sandrone R, Castagneri C, Barbero D, Lo Schirico M, Arcaini L, Molinari AL, Ballerini F, Ferreri A, Omedè P, Zamò A, Balestra G, Boccadoro M, Cortelazzo S, Ladetto M.

JCO Clin Cancer Inform. 2019 Oct;3:1-15. doi: 10.1200/CCI.19.00049.

3.

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomez da Silva M, Santoro A, Molinari A, Ferreri A, Grønbæk K, Piccin A, Cortelazzo S, Bertoni F, Ladetto M, Gaidano G.

Haematologica. 2019 Sep 19. pii: haematol.2018.214056. doi: 10.3324/haematol.2018.214056. [Epub ahead of print]

4.

Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT.

Cesaro S, Tridello G, van der Werf S, Bader P, Sociè G, Ljungman P, McQuaker G, Giardino S, Uckan-Cetinkaya D, Anagnostopoulos A, Ozdogu H, Schots R, Jindra P, Ladetto M, Schroyens W, Mikulska M, Styczynski J.

Bone Marrow Transplant. 2019 Aug 21. doi: 10.1038/s41409-019-0644-8. [Epub ahead of print]

PMID:
31435035
5.

Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network.

Hematol Oncol. 2019 Oct;37(4):368-374. doi: 10.1002/hon.2652. Epub 2019 Aug 16.

PMID:
31325190
6.

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).

Salvi F, Luminari S, Tucci A, Massidda S, Liberati AM, Stelitano C, Zanni M, Re A, Centurioni R, Freilone R, Musuraca G, Nassi L, Patti C, Arcari A, Tani M, Pulsoni A, Pavone V, Volpetti S, Peli A, Evangelista A, Spina M, Ladetto M, Merli F.

Leuk Lymphoma. 2019 Dec;60(12):2890-2898. doi: 10.1080/10428194.2019.1608529. Epub 2019 Jul 8.

PMID:
31282794
7.

A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.

D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Bo MD, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R.

Haematologica. 2019 Sep;104(9):e410-e414. doi: 10.3324/haematol.2018.212811. Epub 2019 Feb 28. No abstract available.

8.

Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.

Grimaldi D, Genuardi E, Ferrante M, Ferrero S, Ladetto M.

Curr Treat Options Oncol. 2018 Nov 6;19(12):71. doi: 10.1007/s11864-018-0594-1. Review.

PMID:
30402764
9.

Methods and role of minimal residual disease after stem cell transplantation.

Ladetto M, Böttcher S, Kröger N, Pulsipher MA, Bader P.

Bone Marrow Transplant. 2019 May;54(5):681-690. doi: 10.1038/s41409-018-0307-1. Epub 2018 Aug 16.

PMID:
30116018
10.

STAble: a novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow.

Saggese I, Bona E, Conway M, Favero F, Ladetto M, Liò P, Manzini G, Mignone F.

BMC Bioinformatics. 2018 Jul 9;19(Suppl 7):184. doi: 10.1186/s12859-018-2174-6.

11.

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Aug 1;29(8):1687-1700. doi: 10.1093/annonc/mdy167.

PMID:
29924296
12.

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133. No abstract available.

PMID:
29878045
13.

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080. No abstract available.

PMID:
29796651
14.

Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.

Drandi D, Ferrero S, Ladetto M.

Methods Mol Biol. 2018;1768:229-256. doi: 10.1007/978-1-4939-7778-9_14.

PMID:
29717447
15.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A.

Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4.

PMID:
29616865
16.

Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia.

Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jiménez C, Guerrini F, Schirico ML, Mantoan B, Muccio V, Lia G, Zaccaria GM, Omedè P, Passera R, Orsucci L, Benevolo G, Cavallo F, Galimberti S, Sanz RG, Boccadoro M, Ladetto M, Ferrero S.

Haematologica. 2018 Jun;103(6):1029-1037. doi: 10.3324/haematol.2017.186528. Epub 2018 Mar 22.

17.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

18.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

19.

Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.

Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network.

Int J Lab Hematol. 2018 Apr;40(2):201-208. doi: 10.1111/ijlh.12766. Epub 2017 Dec 4.

PMID:
29205868
20.

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.

Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Mar 1;29(3):544-562. doi: 10.1093/annonc/mdx413.

PMID:
29194473
21.

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.

Beccuti M, Genuardi E, Romano G, Monitillo L, Barbero D, Boccadoro M, Ladetto M, Calogero R, Ferrero S, Cordero F.

BMC Bioinformatics. 2017 Nov 23;18(1):516. doi: 10.1186/s12859-017-1923-2.

22.

Data quality improvement of a multicenter clinical trial dataset.

Zaccaria GM, Rosati S, Castagneri C, Ferrero S, Ladetto M, Boccadoro M, Balestra G.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:1190-1193. doi: 10.1109/EMBC.2017.8037043.

PMID:
29060088
23.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71. doi: 10.1093/annonc/mdx223. No abstract available.

PMID:
28881919
24.

Infections and Follicular Lymphoma: is there a Link?

Zallio F, Limberti G, Ladetto M.

Mediterr J Hematol Infect Dis. 2017 May 1;9(1):e2017035. doi: 10.4084/MJHID.2017.035. eCollection 2017. Review.

25.

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).

Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, Monaco F, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Visco C, Calabrese M, Limberti G, Levis A, Contino L, Ciccone G, Ladetto M.

Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895. [Epub ahead of print]

PMID:
28447710
26.

Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.

Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S.

Br J Haematol. 2018 Jun;181(5):693-695. doi: 10.1111/bjh.14681. Epub 2017 Apr 2. No abstract available.

PMID:
28369711
27.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; & the ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Feb 1;29(2):525. doi: 10.1093/annonc/mdx061. No abstract available.

PMID:
28368466
28.

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2017 Dec 1;28(12):3109. doi: 10.1093/annonc/mdx020. No abstract available.

PMID:
28327933
29.

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.

J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

30.

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.

Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12. No abstract available.

31.

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ.

J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.

PMID:
28029309
32.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U.

Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

PMID:
27927586
33.

Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.

Catania G, Monaco F, Limberti G, Alessio M, De Martino I, Barile C, Fasciolo A, Baraldi A, Ladetto M, Fusco V.

Dent J (Basel). 2016 Dec 1;4(4). pii: E45. doi: 10.3390/dj4040045.

34.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2016 Dec;27(12):2149-2160. doi: 10.1093/annonc/mdw419. Epub 2016 Oct 4. Erratum in: Ann Oncol. 2018 Feb 1;29(2):525.

35.

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v83-v90. No abstract available. Erratum in: Ann Oncol. 2017 Dec 1;28(12 ):3109.

36.

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v91-v102. Epub 2016 Jul 4. No abstract available.

PMID:
27377716
37.

A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease.

Zallio F, Mazzucco L, Monaco F, Astori MR, Passera R, Drago G, Tamiazzo S, Rapetti M, Dolcino D, Guaschino R, Pini M, Ladetto M.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1664-1670. doi: 10.1016/j.bbmt.2016.05.023. Epub 2016 Jun 4.

38.

PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).

Santi RM, Ceccarelli M, Catania G, Monagheddu C, Evangelista A, Bernocco E, Monaco F, Federico M, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Calabrese M, Levis A, Visco C, Contino L, Ciccone G, Ladetto M.

Thromb Res. 2016 Apr;140 Suppl 1:S177. doi: 10.1016/S0049-3848(16)30136-0. Epub 2016 Apr 8.

PMID:
27161692
39.

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17.

PMID:
26972651
40.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N.

Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Review.

41.

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden KL, Cerchietti L.

Blood. 2016 Feb 18;127(7):858-68. doi: 10.1182/blood-2015-05-645069. Epub 2015 Nov 24.

42.

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B.

Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6. No abstract available.

43.

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M.

J Mol Diagn. 2015 Nov;17(6):652-60. doi: 10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28.

PMID:
26319783
44.

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v116-25. doi: 10.1093/annonc/mdv304. No abstract available.

45.

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v108-15. doi: 10.1093/annonc/mdv201. No abstract available.

46.

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.

Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M.

Oncotarget. 2015 Oct 6;6(30):29833-46. doi: 10.18632/oncotarget.4006.

47.

Epigenomic evolution in diffuse large B-cell lymphomas.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R, Melnick AM, Inghirami GG, Tam W, Elemento O.

Nat Commun. 2015 Apr 20;6:6921. doi: 10.1038/ncomms7921.

48.

Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use?

Giunta F, Zotta M, Menga M, Balma M, Bellò M, Passera R, Filippi AR, Chiappella A, Ladetto M, Ricardi U, Vitolo U, Bisi G.

Q J Nucl Med Mol Imaging. 2015 Jun;59(2):214-9. Epub 2015 Feb 11.

PMID:
25669764
49.

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.

Arcaini L, Morello L, Tucci A, Rusconi C, Ladetto M, Rattotti S, Bonfichi M, Bottelli C, Gabutti C, Bernasconi P, Varettoni M, Gotti M, Troletti D, Guerrera ML, Fiaccadori V, Sciarra R, Ferretti VV, Alessandrino EP, Rossi G, Morra E.

Am J Hematol. 2015 Mar;90(3):230-4. doi: 10.1002/ajh.23919.

50.

Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.

Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M.

Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14.

Supplemental Content

Loading ...
Support Center